PHM.MC实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 23:35):

Stats
今日成交量	48 516.00
平均成交量	39 000.00
市值	555.51M
EPS	€0 ( 2024-04-24 )
下一个收益日期	( €0 ) 2024-07-25
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	283.09
ATR14	€0.0730 (0.23%)

音量相关性

長: -0.07 (neutral)

短: -0.11 (neutral)

Signal:(42.856) Neutral

Pharma Mar, S.A. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Pharma Mar, S.A. 相关性 - 货币/商品

-0.18
( neutral )

0.52
( weak )

0.00
( neutral )

-0.21
( neutral )

-0.49
( neutral )

Pharma Mar, S.A. 财务报表

Annual	2023
营收:	€158.15M
毛利润:	€144.86M (91.60 %)
EPS:	€0.0635

FY	2023
营收:	€158.15M
毛利润:	€144.86M (91.60 %)
EPS:	€0.0635

FY	2022
营收:	€196.34M
毛利润:	€182.70M (93.05 %)
EPS:	€2.73

FY	2021
营收:	€229.83M
毛利润:	€213.39M (92.85 %)
EPS:	€5.14

Financial Reports:

No articles found.

Pharma Mar, S.A.

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.